Financial OutlookThe company anticipates corporate profitability by the end of the year, promoting a positive future outlook for investors.
Regulatory ApprovalThe company's repotrectinib was approved by NMPA for ROS1-positive NSCLC in China, signaling potential for market expansion and revenue growth.
Sales PerformanceNiraparib, a drug from Zai Lab, recorded impressive monthly sales, showcasing strong market adoption and demand.